Contract Pharma Staff04.08.20
Immunologix Laboratories has appointed Lauren Stevenson, Ph.D. as Chief Scientific Officer, expanding the Translational Sciences team. Also, Christopher Stebbins, Ph.D. joins the company as Scientific Director.
Dr. Stevenson has more than 25 years of drug development experience, which spans numerous disease indications and drug modalities. In this role, she will ensure science-first collaborations with clients to help deliver strategy and results, while also maximizing synergies between Immunologix's assay experts and the Translational Sciences Directors.
Dr. Stevenson joined the company in April 2019, following her post as Senior Director and Head, Development Biomarkers & Bioanalytical Sciences at Biogen. Together, with Dr. Devangi Mehta, she co-founded Translational Sciences in May 2019 and will continue to lead that function as part of her new role.
"With Dr. Stevenson as Chief Scientific Officer, we are excited about the enhanced scientific and strength-focused team leadership she is bringing to our organization, as well as accelerating our industry-impacting initiatives," notes Immunologix Laboratories President and CEO, Dr. Michael Anderson. "We are already seeing immediate and demonstrated benefits for both our clients and internal scientists as she builds upon her deep strategic, scientific and results-oriented experience. Dr. Stevenson's appointment further strengthens our industry leading scientific leadership team."
Also, Dr. Stebbins brings two decades of drug development experience in large pharma/biotech, with expertise in building and executing on strategies for both biomarker and bioanalytical development. Dr. Stebbins joins the company from Biogen, where he served as Director, Development Biomarkers & Bioanalytical Sciences.
Dr. Stevenson has more than 25 years of drug development experience, which spans numerous disease indications and drug modalities. In this role, she will ensure science-first collaborations with clients to help deliver strategy and results, while also maximizing synergies between Immunologix's assay experts and the Translational Sciences Directors.
Dr. Stevenson joined the company in April 2019, following her post as Senior Director and Head, Development Biomarkers & Bioanalytical Sciences at Biogen. Together, with Dr. Devangi Mehta, she co-founded Translational Sciences in May 2019 and will continue to lead that function as part of her new role.
"With Dr. Stevenson as Chief Scientific Officer, we are excited about the enhanced scientific and strength-focused team leadership she is bringing to our organization, as well as accelerating our industry-impacting initiatives," notes Immunologix Laboratories President and CEO, Dr. Michael Anderson. "We are already seeing immediate and demonstrated benefits for both our clients and internal scientists as she builds upon her deep strategic, scientific and results-oriented experience. Dr. Stevenson's appointment further strengthens our industry leading scientific leadership team."
Also, Dr. Stebbins brings two decades of drug development experience in large pharma/biotech, with expertise in building and executing on strategies for both biomarker and bioanalytical development. Dr. Stebbins joins the company from Biogen, where he served as Director, Development Biomarkers & Bioanalytical Sciences.